FrontPage is India's Stock Market Social Network
Join 3,00,000+ Traders and Investors
GLAND
10123456789,801234567897012345678970123456789.9012345678950123456789
+132.85 (+7.61%)
Previous Close: 1745.1
1D
5D
1M
3M
1Y
5Y
Popular Posts

Valid CHARTS

MediTrading

Revanth Nifty Radar

*Stocks in News* Equitas Small Finance Bank: Veteran banker P N Vasudevan has resigned as the managing director and chief executive officer of Equitas Small Finance Bank, the lender informed the stock exchanges. Vasudevan, in his resignation letter, said he wants to devote his time towards social welfare through his public charitable trust. HPCL: State-run oil refiner and marketer Hindustan Petroleum Corporation posted a 34 percent decline in consolidated net profit in the March quarter to Rs 2,019 crore from Rs 3,061 crore in the year-ago period due to rise in total cost. Revenue for the quarter stood at Rs 1.07 trillion, up 24.2 percent from Rs 85,755 crore last year. Total cost rose 28 percent to Rs 1.05 trillion from Rs 81,717 crore a year ago. Operating margin for the quarter contracted sharply to 1.57 percent from 4.46 percent last year. Average gross refining margin during the year ended March 2022 was $7.19 per barrel as against $3.86 per bbl during the corresponding previous year. Godrej Consumer Products: Godrej Consumer reported a 1 percent fall in net profit for the March quarter to Rs 363 crore year-on-year as a slowdown in consumption and high commodity inflation weighed. Revenue rose 7 percent from a year ago to Rs 2,920 crore. Total cost rose 12 percent year-on-year to Rs 2,540 crore. Gland Pharma: Gland Pharma's net profit rose 10 percent to Rs 285.90 crore in the quarter ended March 2022 as against Rs 260.41 crore during the same quarter previous fiscal. Net sales rose 24.25 percent to Rs 1,103.01 crore as against Rs 887.75 crore a year ago. EBITDA margin contracted sharply to 35 percent from 40 percent year-on-year. Ashok Leyland: The company reported a 274 percent YoY jump in net profit at Rs 901.4 crore for the fourth quarter of FY22. Total income stood at Rs 8,744.3 crore during the quarter, up 24.9 percent against Rs 7,000.5 crore in the corresponding period of the preceding fiscal. Its truck market share for Q4 FY22 has improved to 30.6 percent against 28.9 percent in Q4 FY21, this is the highest market share seen in the last 11 quarters. Biocon: Subsidiary Biocon Biologics, and Viatris Inc. announced that Abevmy (bBevacizumab) is now available in Canada. Abevmy, co-developed by Biocon Biologics and Viatris, is a biosimilar to Roche's Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications. Eros International: Its board approved raising Rs 405 crore by issuing 13.50 crore warrants at a price of Rs 30 a share. #BIOCON #ASHOKLEY #GLAND #HINDPETRO #GODREJCP

TradeAdda

Good News : 1. Zydus lifescience going to buyback shares #ZYDUSLIFE 2. HPCL profit rise 106% #HINDPETRO 3. Gland Pharma profit rise 9.8% #GLAND 4. Ashok Leyland profit rise 273% #ASHOKLEY 5. GMM Pfaudler going to give bonus #GMMPFAUDLR Chemical, Finance, Pharma and Textile stocks will go upside today

Kishore kumar Ganta

Gland Pharma March 2022 (Quarterly) PAT at Rs 286 crore VS Rs 260 crore YOY. Revenue at Rs 1103 crore VS Rs 888 crore YOY.. #GLAND

BankNifty Expert

STOCKS in ACTION 21 Apr Ajanta Soya Ltd board approves stock split Dhanvarsha Finvest allots 13,00,989 equity shares on conversion of warrants Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market Nykaa : Aveda partners with India's Leading Lifestyle Retailer, Nykaa, to launch Prestige Salons in the Country MDL launches 6th Scorpene Sumbarine of Project-75 - VAGSHEER Tata Steel: The company has stopped doing business with Russia. All steel manufacturing sites in India, the UK and the Netherlands are now sourcing raw material from elsewhere L&T: India's largest engineering firm has signed a memorandum of understanding with the Indian Navy to become its knowledge partner for nurturing various technologies in electrical, weapon, engineering, machinery and control, and hull of a naval warship Oil India: has commissioned a green hydrogen pilot plant at its Jorhat, Assam, pump station to produce 10 kg of the clean fuel per day. It has initiated a detailed study to explore blending of green hydrogen with natural gas and its effect on the existing infrastructure of Oil India Fino Payments Bank receives RBI approval to offer FD and RD services of Suryoday Small Finance Bank PNC Infratech received Rs. 37.0 crore early completion bonus for Purvanchal Expressway - Package VI EPC Project Infosys completes acquisition of Digital Experience and Marketing Agency, oddity Gland Pharmaceuticals: Nicomac Machinery is selling 20.45 lakh shares equivalent to 1.5% stake in Gland Pharma. The floor price has been set at Rs 3,118 per share. There is an option to upsize the deal #DRREDDY #TATASTEEL #GLAND #OIL #NYKAA

EqmOptiontrading

BUDGET 2022 & HEALTHCARE – A STORY OF MISSED EXPECTATIONS? After a 137% YoY increase in allocation, hopes for the healthcare sector with respect to the Budget remained high amidst a resurging COVID-19 crisis, remained rather high. However, reactions to the actual budget proposals and allocations, have been…mixed, to say the least. WHAT THE BUDGET PROMISED? What can be termed as the most novel of the proposals in this sector lies in the government’s path-breaking move of introducing the Ayushman Bharat Digital Mission in the budget with the objective of ensuring universal access to healthcare facilities, across the country from a long-run perspective. However, on the opposite end of the spectrum, the government’s biggest miss lay in the fact that there were absolutely no policy amendments facilitating the participation on the part o the private players with the express objective of providing an impetus in strengthening the country-wide healthcare infrastructure as well as alleviate the immediate healthcare-services-access dilemma. A second aspect of the Healthcare budget that has hogged the limelight has been the focus on Mental Health & Digitisation, with large scale allocation to a National-Tele Mental Health programme as well as an open platform for the national digital health ecosystem consisting of digital registries of health providers and health facilities, unique health identity and universal access to health facilities WHAT IT SHOULD/COULD HAVE PROMISED? In terms of the impact that we can expect due to the budget outlay in this sector, we must take a look at the government’s extension of benefit of the concessional tax regime, applicable to manufacturing companies. Denoting the pharmaceutical sector as one of the sunrise opportunity sectors, the government plans to ensure that the sector should receive its fair share of benefit from future supportive policies. While this sounds well in theory and at an oratory level there have been no moves in consideration to the long-standing demand/expectation of industry to incentivise research and development needed to enable India to move from being an incremental innovator to becoming a global player in innovative drugs. On a different front, we see that the budget outlay for public-hospitals has increased by 30%, but along the same lines, the much-needed investment for strengthening the surveillance system has seen only a mere 16.4 % increase. The Ayushman Bharat health insurance scheme remains to be grossly underfunded and allocated the same amount as last year. Again a 3.92% increase in healthcare research has led to further disappointments, while the need to build further laboratories out of this budget looms over the industry and prospects of additional funding-aid from the World Bank or ADB in the near horizon, looks bleak. CONCLUSION: The 2022 Budget could have been a landmark year in the healthcare front, empowering the country to develop the resilience required to so that we never go through the disruptions we have witnessed. Sadly, it did little towards bridging the gaps in the system, as we stick to the healthcare expense still being at 1.5% of the GDP. #FORTIS #APOLLOHOSP #GLAND

Voyage Capital

Nirmal Bang target on GLAND Date: 23-Jan-22 Broker: Nirmal Bang Price @ Call: 3570 Target: 3439 Potential: -3.67% Recommendation: ACCUMULATE

ReportBot

Shyamkumar S

Shyamkumar S

Sharekhan target on GLAND Date: 26-Nov-21 Broker: Sharekhan Price @ Call: 3499 Target: 4400 Potential: 25.75% Recommendation: BUY

ReportBot

Alpha Signals

Revanth Nifty Radar

Sharekhan target on GLAND Date: 29-Sep-21 Broker: Sharekhan Price @ Call: 3714 Target: 4400 Potential: 18.47% Recommendation: BUY

ReportBot

Deepak Choudhary

Axis Direct target on GLAND Date: 08-Sep-21 Broker: Axis Direct Price @ Call: 3990 Target: 4100 Potential: 2.76% Recommendation: HOLD

ReportBot

Alok Singh

Strong earnings 💪 1⃣ #HAVELLS : margins at 13.6% vs 8.9% 2⃣ #JUBLFOOD : Revenue up 130% at Rs 893 cr, management says worst is behind 3⃣ #GLAND : Rev Up 31% to 1154cr 4⃣ #SYNGENE : Rev Up 41% to 595cr 5⃣ #ISEC : Highest ever quarterly addition of 3.9 lakh clients

Daily Stock Insight

Alpha Signals

Chartsandequity

Nifty Profit Makers

Gland Pharma Ltd. – Highlights Gland Pharma Ltd. is trading at Rs 3063.85, up by 9.70% on the BSE. The stock is up 25.09% in last three months as compared to a 2.20% drop in S&P Bse Sensex. The rally in the stock is due to its fantastic Q4 FY 2021 results reported on the exchanges on Monday. The Hyderabad-based pharma company posted a net profit of ₹260.41 crore for the Q4 FY 2021, up by 33.69 % against ₹194.79 crore it logged during the Q4 FY 2020. For the fiscal year ended March 31, 2021, the company reported a profit of 996.96 crore, a 29 % increase over the previous year’s profit of 772.86 crore, and income of 3,462.88 crore, a 31.5 % increase over the previous fiscal’s income of 2,633.24 crore. In a regulatory filing, Gland Pharma’s MD and CEO, Srinivas Sadu, stated, “Overall, the business has performed well and grown steadily during these challenging times.” New product launches, volume growth in existing portfolios, and geographic expansion have all contributed to strong business growth across all markets. Our new Vaccine business will help us accelerate our long-term strategy of entering the Biosimilar space.” The company has introduced new products such as Micafungin and Bivalirudin in Ready-to-Use form, as well as Olapatadine, an ophthalmic product in the market. The company has increased Remdesivir supply while maintaining adequate Enoxaparin supply to meet the needs of Covid-19 patients. The Company filed 21 ANDAs (abbreviated new drug applications), 5 DMFs (Drug Master File), and received 32 ANDA approvals during the fiscal year ended March 31, 2021. As at March 31, 2021, the Company has filed total 284 ANDAs, out of which 234 were approved and 50 are pending for approval. The company is expanding its Hyderabad-based sterile injectable facility. It is also expanding its API production capacity in Vizag and expanding capacity in its oncology facility to meet the planned launches in the coming years. Furthermore, the company will invest in the drug substance and biologics facility in order to build a strong infrastructure in the vaccine and bio-similar space. Founded in 1978 in Hyderabad, India, Gland Pharma has evolved from a contract manufacturer of small volume liquid parenteral products to one of the world’s largest and fastest growing injectable-focused companies, with a global footprint spanning 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It primarily operates under a business to business (B2B) model and has an excellent track record in the development, manufacturing and marketing of complex injectables. This presence throughout the value chain has greatly aided in the company’s exponential growth. Shanghai Fosun Pharma, a global pharmaceutical conglomerate, is the company’s promoter. #GLAND #NIFTYPHARMA

Alpha Signals

*Stocks in News* Bharti Airtel: The company reported consolidated profit at Rs 759.2 crore in Q4FY21 against Rs 853.6 crore in Q3FY21, revenue fell to Rs 25,747.3 crore from Rs 26,517.8 crore QoQ. Strides Pharma Science: Promoter Group of the company have released substantial pledge of over 38 percent, taking the current overall promoter group pledge at 25.98% of the promoter holding and 7.71% of the paid up capital of the company. Orient Cement: The company reported sharply higher profit at Rs 99.87 crore in Q4FY21 against Rs 44.06 crore in Q4FY20, revenue jumped to Rs 831.61 crore from Rs 654.52 crore YoY. Wabco India: The company reported higher profit at Rs 47.63 crore in Q4FY21 against Rs 31.49 crore in Q4FY20, revenue jumped to Rs 712.32 crore from Rs 404.85 crore YoY. Gland Pharma: The company reported higher consolidated profit at Rs 260.4 crore in Q4FY21 against Rs 194.79 crore in Q4FY20, revenue rose to Rs 887.7 crore from Rs 635.2 crore YoY. HCL Technologies: The company announced the expansion of investment in United Kingdom with the hiring of 1,000 technology professionals to support its clients in the UK and around the world #GLAND #HCLTECH #BHARTIARTL #STAR #WABCOINDIA

TradeAdda

COMPANY NAME RESULT DATE #BHARTIARTL - 17 May 2021 #BUTTERFLY - 17 May 2021 #COLPAL - 17 May 2021 #FEDERALBNK - 17 May 2021 #GLAND - 17 May 2021 #GNFC - 17 May 2021 #GOKULAGRO - 17 May 2021 #GRSE - 17 May 2021 #ICIL - 17 May 2021 #MRPL - 17 May 2021 #NALINLEA - 17 May 2021 #NUTRICIRCLE - 17 May 2021 #ORIENTCEM - 17 May 2021 #PPL - 17 May 2021 #RBL - 17 May 2021 #SBECSYS - 17 May 2021 #SHAKTIPUMP - 17 May 2021 #SPARC - 17 May 2021 #SUBEX - 17 May 2021 #SURAJLTD - 17 May 2021 #WABCOINDIA - 17 May 2021 #3IINFOTECH - 17 May 2021 #ASITCFIN - 17 May 2021 #ATVPR - 17 May 2021

vijay jaria

Alpha Signals

#GLAND today 2527 - 2665 : Target 2670 & 2775 more....This post in Positional Trades (Swing,Momentum,Trending,Invest) channel on FrontPage

Jagdish Jha

Gland Pharma Q3 (YoY) Net profit up 32% at Rs 204.1 cr Vs Rs 154.1 cr Revenue up 33% at Rs 859.4 cr Vs Rs 646 cr EBITDA up 26% at Rs 299.4 cr Vs Rs 237.1 cr EBITDA margin at 33% Vs 35% #GLAND

Alpha Signals

Missed the IPO, but looks like Gland pharma is soon becoming Grand Pharma ~ up over 50% since listing. Trading @ 30 to 32x FY22 PE. Key positive it seems is margins due to no front end and strong compliance history especially for an injectable co. Why was subscription only 2x? #GLAND

Daily Stock Insight

Company Overview: Gland Pharma (Gland) is one of the fastest growing global pure-play companies in the injectables space. Gland sells its products in more than 60 countries across 5 continents. U.S. accounted for 67% of total sales while India accounted for about 18% sales and balance 15% came from Europe, Canada, Australia and Rest of the World in FY20. The company’s key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, etc. Gland follows the B2B business model in exports and B2C in domestic markets. 96% of revenues in FY20 came from its B2B business. Investment Rationale Injectables space – high growth, niche area with few competitors – According to IQVIA Consulting and Information Services India Pvt. Ltd. – 2020, the share of injectables in the global pharma market is increasing at a rapid rate. Injectables are becoming the preferred way of administering drugs. Gland being a global pure play injectables producer, stands to benefit from the high growth in this segment. Niche products with limited competitors - 40% of Gland’s key molecules have only 5 competitors; another 40% have 4-10 players. Only 20% of the company’s products have more than 10 competitors. With fewer players in this space, the company faces a lower risk of price erosion. Impeccable track record on compliance – Despite having a very high proportion of sales from complex generic injectables from US, Gland has maintained an impeccable track record on compliance. The company has not received any warnings or observations from the USFDA in the last 5 years. #GLAND

TradeAdda

#InvestmentIdeas #GLAND Company Overview: Gland Pharma (Gland) is one of the fastest growing global pure-play companies in the injectables space. Gland sells its products in more than 60 countries across 5 continents. U.S. accounted for 67% of total sales while India accounted for about 18% sales and balance 15% came from Europe, Canada, Australia and Rest of the World in FY20. The company’s key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, etc. Gland follows the B2B business model in exports and B2C in domestic markets. 96% of revenues in FY20 came from its B2B business. Investment Rationale Injectables space – high growth, niche area with few competitors – According to IQVIA Consulting and Information Services India Pvt. Ltd. – 2020, the share of injectables in the global pharma market is increasing at a rapid rate. Injectables are becoming the preferred way of administering drugs. Gland being a global pure play injectables producer, stands to benefit from the high growth in this segment. Niche products with limited competitors - 40% of Gland’s key molecules have only 5 competitors; another 40% have 4-10 players. Only 20% of the company’s products have more than 10 competitors. With fewer players in this space, the company faces a lower risk of price erosion. Impeccable track record on compliance – Despite having a very high proportion of sales from complex generic injectables from US, Gland has maintained an impeccable track record on compliance. The company has not received any warnings or observations from the USFDA in the last 5 years.

Sridhar Balakrishnan

Kewat Ajay-display-image
Reputation: 446  •  Nov 14 3:29 AM

Study Analysis: A good Pharma stock is at make or break turning point. #GLAND . #Pharma stock. If this holds 1700 level a good upside move is expected... let's see how good this analysis works...
Chartbusters - chart - 15973618
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Oct 31 4:53 AM
Gland Pharma sinks on fears of distress sale by Chinese owner
Gland Pharma’s earnings for the September quarter have also done little to ease investors’ anxiety given that the company reported a sharp decline in net profit
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Oct 28 10:53 AM
Buy Gland Pharma; target of Rs 2260: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated October 27, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Add a comment
Add a comment
Valid CHARTS -display-image
Reputation: 4,075  •  Oct 8 3:14 AM

Jab list huya vaha se double ho gya aur fr vapis vaha aa gya😂
Timeframe - weekly
Chartbusters - chart - 13645462
1 Like
2 Comments
Share
Add a comment
Ankit-display-image
Reputation: 2,668  •  Sep 27 12:42 PM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Sep 2 12:23 PM
Trade Spotlight | What should you do with ABB India, Gland Pharma, Schneider Electric Infra on Friday?
Gland Pharma jumped 5.6 percent to Rs 2,501 and formed small bodied bullish candle on the daily scale, while Schneider Electric Infrastructure climbed over 6 percent to Rs 145.3 and Inverted Hammer kind of pattern on the daily charts with above average volumes.
Moneycontrol
Like
Comment
Share
Add a comment
Wealth Mentors-display-image
Reputation: 830  •  Sep 1 8:18 AM

BTST
GLAND
Cmp: 2511
TGT: 2540- 2580- 2700
Sl: 2460
Cash
Like
Comment
Share
Add a comment
MediTrading-display-image
Reputation: 726  •  Aug 25 7:52 AM

#GLAND GLAND PHARMA - readying for some decent up moves. All levels mentioned on the chart.
Chartbusters - chart - 11882531
2 Likes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Jul 21 3:03 AM
Buy Gland Pharma; target of Rs 3080: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3080 in its research report dated July 20, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Revanth Nifty Radar-display-image
Reputation: 15,352  •  Jul 21 2:17 AM
1 Like
Comment
Share
Add a comment
Add a comment
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  Jul 18 12:30 PM

#GLAND will declare results on Jul 20, 2022
Please plan your trades accordingly 😎
Like
Comment
Share
Add a comment
morninghaze-display-image
Reputation: 4,028  •  Jul 13 4:18 AM

#GLAND Gland falling below 52 week low -- my own belief that stock fall closes below 2350, stock will be decimated --stock is long term underperformer(DYOR)(paper trading)
text_snippet
stock charts.docx
164 KB
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Jun 27 8:03 AM
Buy Gland Pharma; target of Rs 3700: Motilal Oswal
Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3700 in its research report dated June 25, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Jun 21 4:13 AM
Gland Pharma surges as CLSA India initiates coverage with buy rating
The brokerage firm expects Gland Pharma to deliver 15-20 percent growth in revenues over the next three years
Moneycontrol
Like
Comment
Share
Add a comment
W
Reputation: 989  •  Jun 17 6:59 AM

GLAND PHARMA : RS 129.53CR NSE BLOCK TRADE; FOR ~500102 SHARES, AT RS 2590
block deal #GLAND
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  May 21 2:08 AM
Buy Gland Pharma: target of Rs 3770: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3770 in its research report dated May 20, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
TradeAdda-display-image
Reputation: 54,335  •  May 20 2:07 AM

*Stocks in News*
Equitas Small Finance Bank: Veteran banker P N Vasudevan has resigned as the managing director and chief executive officer of Equitas Small Finance Bank, the lender informed the stock exchanges. Vasudevan, in his resignation letter, said he wants to devote his ti......read more
1 Like
Comment
Share
Add a comment
Kishore kumar Ganta -display-image
Reputation: 4,740  •  May 20 1:02 AM

Good News :
1. Zydus lifescience going to buyback shares
2. HPCL profit rise 106%
3. Gland Pharma profit rise 9.8%
4. Ashok Leyland profit rise 273%
5. GMM Pfaudler going to give bonus
Chemical, Finance, Pharma and Textile s......read more
1 Like
4 Comments
Share
Add a comment
BankNifty Expert-display-image
Reputation: 46,455  •  May 19 3:03 AM

Gland Pharma March 2022 (Quarterly) PAT at Rs 286 crore VS Rs 260 crore YOY. Revenue at Rs 1103 crore VS Rs 888 crore YOY..
1 Like
Comment
Share
Add a comment
Add a comment
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  May 17 12:30 PM

#GLAND will declare results on May 19, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Apr 21 4:48 AM
Bulk deals | Menu exits Barbeque Nation, Nicomac Machinery cuts stake in Gland Pharma
Menu Private Limited sold all its 5,05,504 equity shares in Barbeque at an average price of Rs 1,163 apiece. The stock on April 21 rose 1.4 percent to Rs 1,178.
Moneycontrol
Like
Comment
Share
Add a comment
StocksnMore-display-image
Reputation: 1,032  •  Apr 21 7:07 AM
StocksnMore in GLAND
#GLAND
Like
Comment
Share
Add a comment
EqmOptiontrading-display-image
Reputation: 828  •  Apr 21 2:30 AM

STOCKS in ACTION 21 Apr

Ajanta Soya Ltd board approves stock split

Dhanvarsha Finvest allots 13,00,989 equity shares on conversion of warrants

Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market

Nykaa : Aveda partners with......read more
1 Like
Comment
Share
Add a comment
StocksnMore-display-image
Reputation: 1,032  •  Apr 21 2:01 AM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Apr 20 1:23 AM
Nicomac Machinery to sell 1.5% stake in Gland Pharma via block deals tomorrow
The company is selling about 2.45 million shares, which accounts for around 1.5 percent of the total outstanding shares, reports said, citing the terms of the deal.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,722  •  Apr 20 7:58 AM
Buy Gland Pharma; target of Rs 4040: Motilal Oswal
Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 4040 in its research report dated April 19, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Nifshots -display-image
Reputation: 1,199  •  Apr 6 2:55 AM
Like
Comment
Share
Add a comment
TechMentalAK-display-image
Reputation: 11,938  •  Apr 6 10:58 AM

GLAND PHARMA LTD
Daily Timeframe
1️⃣ RSI divergence indicating change in polarity
2️⃣ BreakOut above trendline (but with inadequate volume)
3️⃣ Double bottom pattern
⭐ CMP 3335
📈 Important levels marked on the chart
Chartbusters - chart - 8582968
Like
Comment
Share
Add a comment
X
Reputation: 272  •  Apr 5 2:03 AM

#GLAND looks promising above 3400 for upside, Support 3280, Target 3575+
Chartbusters - chart - 8532262
Like
Comment
Share
Add a comment
Traders Premier -display-image
Reputation: 2,324  •  Feb 9 12:04 PM

Positional Call NSE:GLAND CMP 3520 buy above 4062.95 stop loss 3242.15 #turtletrade Educational purpose only
Like
Comment
Share
Add a comment
Voyage Capital-display-image
Reputation: 2,707  •  Feb 2 5:01 AM

BUDGET 2022 & HEALTHCARE – A STORY OF MISSED EXPECTATIONS?

After a 137% YoY increase in allocation, hopes for the healthcare sector with respect to the Budget remained high amidst a resurging COVID-19 crisis, remained rather high. However, reactions to the actual budget proposal......read more
2 Likes
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,713  •  Jan 29 12:30 PM

Axis Direct target on GLAND
Date: 25-Jan-22 Broker: Axis Direct Price @ Call: 3250 Target: 3570 Potential: 9.85% Recommendation: HOLD
Like
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,713  •  Jan 25 3:30 AM

Motilal Oswal target on GLAND
Date: 22-Jan-22 Broker: Motilal Oswal Price @ Call: 3570 Target: 4240 Potential: 18.77% Recommendation: BUY
Like
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,713  •  Jan 24 6:30 AM

Nirmal Bang target on GLAND
Date: 23-Jan-22 Broker: Nirmal Bang Price @ Call: 3570 Target: 3439 Potential: -3.67% Recommendation: ACCUMULATE
3 Likes
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  Jan 19 12:30 PM

#GLAND will declare results on Jan 21, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
Jagdish Jha-display-image
Reputation: 8,134  •  Jan 5 6:26 AM

#GLAND 3983 : Crossed Target 3975, next 4095 & more in
Early Recommendations 3875 to 3983
This post in Trades (Swing,Momentum,Trending,Invest) channel on FrontPage
1 Like
Comment
Share
Add a comment
Shantanu -display-image
Reputation: 461  •  Jan 4 10:30 AM

Positional view.
Gland Pharma looks good above 3950.
SL 3800 closing basis.
Target 4050-4150-4250++
RR-1:2
Like
2 Comments
Share
Add a comment
Shyamkumar S-display-image
Reputation: 17,304  •  Dec 29, 2021 2:34 AM
Shyamkumar S in GLAND
Positional Stock Veiw : #GLAND Is Forming Bull...

Flying From 3600 to 3900 Waiting For 4000 Levels #GLAND
Like
Comment
Share
Add a comment
Shyamkumar S-display-image
Reputation: 17,304  •  Dec 24, 2021 2:03 AM
Shyamkumar S in GLAND
Positional Stock Veiw : #GLAND Is Forming Bull...

I Suggested On 3600 Levels And Now Trading At 3800 Levels More Expected Target Is 4000 #GLAND
Updated Chart Is Attached Below
Chartbusters - chart - 6535440
1 Like
Comment
Share
Add a comment
Jagdish Jha-display-image
Reputation: 8,134  •  Dec 23, 2021 8:24 AM

#GLAND 3875 : Target 3975 & more in Trades
1 Like
Comment
Share
Add a comment
Shyamkumar S-display-image
Reputation: 17,304  •  Dec 11, 2021 1:12 AM

Positional Stock Veiw : #GLAND Is Forming Bullish Flag Pole Pattern In Weekly Time Frame Chart Expected A Breakout Move In Upcoming Weeks
Breakout Or Price Close Above 3725 Can Take To The Target Levels Of 4300 Levels
Stoploss Can Be Kept Below 3340 Levels
Best Investment Stock......read more
Chartbusters - chart - 6318958
2 Likes
Comment
Share
Add a comment
Deepak Choudhary-display-image
Reputation: 1,345  •  Dec 5, 2021 1:08 AM

$GLAND what was resistance now acting as support Buy signal
Entry : 3530
Target : 4357
Stop loss : 3300

GLAND - 6199700
Like
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,713  •  Nov 30, 2021 11:30 AM

Sharekhan target on GLAND
Date: 26-Nov-21 Broker: Sharekhan Price @ Call: 3499 Target: 4400 Potential: 25.75% Recommendation: BUY
2 Likes
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,713  •  Nov 24, 2021 6:30 AM

Nirmal Bang target on GLAND
Date: 24-Nov-21 Broker: Nirmal Bang Price @ Call: 3525 Target: 3533 Potential: 0.23% Recommendation: ACCUMULATE
Like
Comment
Share
Add a comment